- Conditions
- Hepatic Impairment
- Interventions
- AZD6234, AZD9550
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Chandler, Arizona • Rialto, California • Miami Lakes, Florida + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hepatic Impairment
- Interventions
- AZD2389
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 5
- States / cities
- Chandler, Arizona • Rialto, California • Miami Lakes, Florida + 2 more
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
- Interventions
- Elinzanetant (BAY3427080)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Neoplasms, Non-hematologic - Stage I-III
- Interventions
- Not listed
- Lead sponsor
- Lexent Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Lung Cancer, Precancerous Condition
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2009
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Renal Impairment
- Interventions
- Opemalirsen (AZD2373)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Metastatic Cancer
- Interventions
- Pixantrone
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Newly-diagnosed Cancers, Non-cancer Controls
- Interventions
- Freenome Test
- Diagnostic Test
- Lead sponsor
- Freenome Holdings Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 788 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 23
- States / cities
- Cordele, Georgia • Orland Park, Illinois • Park Ridge, Illinois + 20 more
- Conditions
- Healthy, no Evidence of Disease, Lung Cancer
- Interventions
- proteomic profiling, biologic sample preservation procedure, laboratory biomarker analysis, bronchoscopy
- Genetic · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Hodgkin's Lymphoma
- Interventions
- Tacrolimus (ARM with Methotrexate), Tacrolimus (ARM with MMF and Cyclophosphamide), Methotrexate (ARM with Maraviroc), Methotrexate (ARM with Bortezomib), Maraviroc, Bortezomib, Mycophenolate mofetil, Cyclophosphamide
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 30
- States / cities
- Duarte, California • Stanford, California • Gainesville, Florida + 24 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- N-Power Medicine
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- Monterey, California • Dover, Delaware • Milford, Delaware + 5 more
- Conditions
- Colorectal Cancer (Diagnosis), Non-cancer Controls, DNA Methylation, Cell Free DNA, Early Detection of Cancer
- Interventions
- Not listed
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Monrovia, California